Author: @admin

Post

Iterum Therapeutics Reports First Quarter 2021 Financial Results

FDA Review of NDA for Oral Sulopenem Continues; Current Prescription Drug User Fee Act (PDUFA) date of July 25, 2021 Cash Runway into First Half of 2023 Company to host conference call today at 8:30am ET DUBLIN, Ireland and CHICAGO, May 14, 2021 (GLOBE NEWSWIRE) — Iterum Therapeutics...

Post

Cidara Provides Corporate Update and Reports First Quarter 2021 Financial Results

SAN DIEGO, May 13, 2021 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today reported financial results for the three months ended March 31, 2021 and provided an update on its corporate activities and product...

Post

Summit Therapeutics Announces Closing of $75 Million Rights Offering

Cambridge, MA, May 12, 2021 – Summit Therapeutics Inc. (NASDAQ: SMMT) announced today the successful closing of its fully subscribed rights offering and the associated results. The rights offering resulted in the sale of 14,312,976 shares of the Company’s common stock, par value $0.01 (the “Shares,” and each, a “Share”) at a price of $5.24...

Post

SCYNEXIS Appoints Accomplished Commercial Executive Christine Coyne as Chief Commercial Officer to Lead the Brexafemme® Launch

SCYNEXIS Appoints Accomplished Commercial Executive Christine Coyne as Chief Commercial Officer to Lead the Brexafemme® Launch Strengthening the management team with deep anti-infective commercial expertise across hospital and community settings ahead of anticipated approval of Brexafemme (ibrexafungerp) in June 2021 and H2:2021 launch JERSEY CITY, N.J., May 11, 2021...

Post

Iterum Therapeutics to Provide Business Update and Report First Quarter 2021 Financial Results on May 14, 2021

DUBLIN, Ireland and CHICAGO, May 07, 2021 (GLOBE NEWSWIRE) — Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that the Company will release...

Post

Nabriva Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Updates

-First quarter of full complement of 60 sales representatives further expanding the reach of XENLETA® (lefamulin) and SIVEXTRO® (tedizolid phosphate) in the community- -Commenced exclusive distribution of SIVEXTRO in the U.S. on April 12, 2021 and moving forward will record 100% of net product sales of SIVEXTRO in results of operations- -Conference call today at...

Post

Summit Therapeutics Publishes Scientific Updates to Corporate Website

Cambridge, MA, May 5, 2021 – Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that we have updated the scientific and related content on our corporate website with respect to our investigational drug, ridinilazole, which is currently enrolling patients in its Phase 3 clinical trials.  The content provides scientific data in a consumable manner, summarizing the...

Post

Entasis Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update

– ATTACK Phase 3 topline data readout remains on track for second half of 2021 –            – Strengthened balance sheet with $20M financing – WALTHAM, Mass., May 05, 2021 (GLOBE NEWSWIRE) — Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced today its first...

Post

Summit Therapeutics’ Rights Offering Nearing Expiration Date; Robert W. Duggan Declares Intention to Fully Oversubscribe in the Rights Offering

Cambridge, MA, May 5, 2021 – Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that it is nearing the previously-announced expiration date for its rights offering of 5:00 pm Eastern Daylight Time on May 10, 2021 (the “Expiration Date”).  Importantly, for stockholders whose shares of our common stock are held in a brokerage account or are...